Sep 8 2009
The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces the successful completion of the Recruitment for the Phase IIa clinical trial assessing the new short-acting intravenous anesthetic/sedative CNS 7056 in patients undergoing endoscopy of the upper gastrointestinal tract.
“Again our development team has beaten our expectations. We will be able to provide headline data by November,” commented Dr. Wolfgang Söhngen, PAION’s CEO. “Based on the blinded data already available there are no safety concerns and we expect that this study will support the unique profile of this exciting compound.”
Initiated in April 2009 the Phase IIa trial was a randomized, double blind, midazolam controlled study examining three doses of CNS 7056 compared with midazolam in 100 patients undergoing a diagnostic endoscopy of the upper gastrointestinal tract. It was designed to further evaluate the safety of CNS 7056 and the success of sedation, as well as the time to full recovery and discharge, in comparison to the gold-standard agent, midazolam.
http://www.paion-jobs.de
Reduction of prenatal depression associated with higher full-term birth rates